Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Rabbit Plasma Lipidomics with high fat diet and treatment (Study ST000781)

C18 NEGATIVE ION MODE (Analysis AN001236)

Metabolite	Structure	F1	F2	F3	F4	F5	F6
CL 66:1; [M-2H](2-)@6.27	ME217491	0.27	0.80	0.86	0.30	2.94	0.87
plasmenyl-PE 38:6; [M-H]-@6.62	ME217692	0.17	2.35	0.56	0.11	1.87	0.94
PA 34:0; [M-H]-@7.97	ME217519	1.72	0.47	0.65	1.30	0.76	1.21
PE 40:6; [M-H]-@6.88	ME217630	1.03	0.62	0.65	1.23	1.64	0.76
PE 40:8; [M-H]-@5.97	ME217631	0.79	0.80	0.98	1.08	1.77	0.60
PE 38:4; [M-H]-@6.92	ME217618	1.15	0.73	0.60	1.75	0.99	0.68
PE 40:5; [M-H]-@7.13	ME217629	1.22	0.74	0.64	1.66	0.98	0.67
PE 37:4; [M-H]-@6.73	ME217612	1.20	0.59	0.58	1.61	1.07	0.85
PE 40:4; [M-H]-@7.41	ME217628	1.07	0.75	0.59	1.58	1.15	0.77
PE 42:9; [M-H]-@6.08	ME217632	1.12	0.76	0.62	1.40	1.29	0.72
PE 39:4; [M-H]-@7.30	ME217625	1.13	0.93	0.52	1.46	1.06	0.79
PS 34:0; [M-H]-@6.40	ME217654	1.30	0.90	0.68	1.33	1.07	0.63
PS 36:2; [M-H]-@6.08	ME217656	0.94	1.38	0.51	1.31	1.16	0.62
PC 39:4; [M-Ac-H]-@7.19	ME217568	0.95	1.40	0.84	1.07	1.02	0.70
PE 39:5; [M-H]-@6.78	ME217626	0.77	1.18	0.61	1.36	1.11	0.92
lysoPE 17:0; [M-H]-@2.11	ME217660	0.90	1.16	0.68	1.06	1.14	1.01
lysoPE 16:0; [M-H]-@1.68	ME217658	0.86	1.27	0.69	1.14	1.12	0.86
PC 41:4; [M-Ac-H]-@7.56	ME217577	0.84	1.27	0.74	1.02	1.25	0.85
PC 40:5; [M-Ac-H]-@7.01	ME217573	0.75	1.10	0.66	0.88	1.47	1.10
PE 36:2; [M-H]-@5.65	ME217603	0.68	1.11	0.72	1.01	1.36	1.10
CL 70:1; [M-2H](2-)@6.86	ME217492	0.71	0.95	0.61	1.10	1.53	1.06
PE 34:1; [M-H]-@6.86	ME217590	0.75	0.94	0.64	1.08	1.41	1.13
CL 72:5; [M-2H](2-)@6.39	ME217494	0.69	0.87	0.77	1.07	1.41	1.17
PE 40:4; [M-H]-@6.08	ME217627	0.74	0.78	0.69	1.08	1.51	1.17
CL 78:9; [M-2H](2-)@6.49	ME217499	0.90	0.83	0.55	1.31	1.45	0.88
PE 38:5; [M-H]-@6.55	ME217621	0.88	0.98	0.57	1.22	1.39	0.88
CL 78:3; [M-2H](2-)@7.55	ME217498	0.63	1.02	0.79	1.18	1.35	1.03
PE 37:3; [M-H]-@6.91	ME217611	0.84	0.95	0.82	1.12	1.34	0.92
PE 35:0; [M-H]-@7.63	ME217594	0.84	0.94	0.73	1.20	1.28	0.97
PE 38:4; [M-H]-@5.61	ME217619	0.84	0.92	0.69	1.22	1.30	0.98
PE 38:6; [M-H]-@6.13	ME217623	0.98	0.75	0.91	1.33	1.26	0.75
PE 30:0; [M-H]-@6.12	ME217584	0.79	1.11	0.90	1.10	1.34	0.77
PS 38:4; [M-H]-@6.06	ME217657	0.69	0.95	0.92	1.31	1.44	0.71
PE 36:0; [M-H]-@7.84	ME217599	1.17	0.63	0.83	0.93	1.18	1.21
PG 38:4; [M-H]-@6.13	ME217639	0.93	0.75	0.65	1.20	1.00	1.40
PE 35:1; [M-H]-@7.14	ME217595	0.99	0.90	0.81	1.32	0.80	1.13
PG 36:2; [M-H]-@6.15	ME217636	1.08	0.77	0.77	1.22	0.83	1.27
PA 34:0; [M-H]-@6.96	ME217517	1.15	0.96	0.80	1.18	1.01	0.87
PE 37:2; [M-H]-@7.30	ME217610	1.16	0.99	0.84	1.26	0.86	0.84
PE 38:3; [M-H]-@7.25	ME217617	1.16	0.72	0.79	1.50	0.93	0.84
PE 35:2; [M-H]-@6.72	ME217596	0.98	0.70	0.82	1.47	0.97	1.02
PE 38:7; [M-H]-@5.60	ME217624	1.05	0.70	0.83	1.38	0.98	1.02
FFA(16:0)	ME217501	0.94	1.05	0.99	1.16	0.90	0.97
FFA(20:0)	ME217505	0.83	1.13	0.96	1.07	1.00	1.02
PC 37:1; [M-Ac-H]-@7.56	ME217554	0.88	1.02	0.98	1.12	1.09	0.92
PA 34:0; [M-H]-@2.83	ME217518	1.03	1.05	1.07	0.83	1.07	0.96
PC 34:0; [M-Ac-H]-@7.19	ME217536	0.99	1.01	0.99	1.00	1.01	1.00
PE 34:0; [M-H]-@7.27	ME217589	1.00	1.01	0.99	1.00	1.01	0.99
PG 34:0; [M-H]-@6.38	ME217633	1.00	1.00	1.00	1.00	1.00	1.00
PI 37:4; [M-H]-@5.66	ME217649	1.01	1.00	1.00	1.00	0.99	1.00
FFA(18:1)	ME217503	0.86	1.05	1.15	1.05	0.83	1.10
FFA(24:0)	ME217512	0.90	1.16	0.93	1.11	0.80	1.10
PE 38:2; [M-H]-@7.56	ME217616	0.65	1.04	1.06	1.17	1.13	1.00
FFA(18:0)	ME217502	0.79	0.96	0.93	1.01	1.10	1.22
PE 36:2; [M-H]-@7.03	ME217602	0.79	0.94	0.89	1.07	1.19	1.12
PE 36:5; [M-H]-@5.71	ME217608	0.71	0.71	1.33	1.02	1.08	1.25
PE 33:2; [M-H]-@6.11	ME217588	0.82	0.78	1.08	1.22	0.99	1.15
PE 37:1; [M-H]-@7.68	ME217609	0.96	0.69	1.03	1.16	1.10	1.07
PC 32:3; [M-Ac-H]-@5.17	ME217531	0.29	1.02	0.87	0.29	1.60	1.98
PC 36:6; [M-Ac-H]-@5.05	ME217553	0.17	0.97	0.87	0.27	1.65	2.12
CL 74:1; [M-2H](2-)@7.45	ME217495	0.67	0.67	0.91	0.85	1.81	1.11
PE 35:4; [M-H]-@6.10	ME217598	0.78	0.60	1.11	0.78	1.60	1.16
PC 35:0; [M-Ac-H]-@7.46	ME217543	0.64	1.15	1.01	0.69	1.49	1.06
PC 40:8; [M-Ac-H]-@5.80	ME217576	0.72	1.05	1.05	0.71	1.47	1.04
PE 36:3; [M-H]-@6.54	ME217605	0.58	1.00	0.92	0.72	1.57	1.24
PE 36:4; [M-H]-@6.22	ME217607	0.53	0.87	1.00	0.67	1.65	1.34
PA 34:2; [M-H]-@6.28	ME217520	0.69	1.51	0.75	1.01	0.96	1.06
PI 38:3; [M-H]-@6.19	ME217650	0.79	1.59	0.81	0.74	1.20	0.86
PC 19:2; [M-Ac-H]-@1.38	ME217521	0.64	1.55	1.04	0.78	1.04	1.00
PC 37:2; [M-Ac-H]-@7.16	ME217555	0.71	1.46	0.94	0.88	1.15	0.88
FFA(24:3)	ME217515	0.57	1.51	0.92	0.69	1.18	1.16
plasmenyl-PE 34:2; [M-H]-@6.72	ME217678	0.64	1.45	0.83	0.77	1.23	1.08
PC 42:5; [M-Ac-H]-@7.43	ME217581	0.54	1.33	0.90	0.81	1.45	0.98
PC 38:3; [M-Ac-H]-@6.86	ME217561	0.64	1.32	0.83	0.73	1.43	1.06
PC 38:3; [M-Ac-H]-@7.13	ME217562	0.64	1.32	0.83	0.73	1.43	1.06
plasmenyl-PE 34:0; [M-H]-@7.34	ME217676	0.77	1.38	0.77	0.82	1.24	0.99
PC 40:4; [M-Ac-H]-@7.30	ME217572	0.69	1.30	0.78	0.83	1.31	1.07
PE 32:0; [M-H]-@6.71	ME217585	0.67	1.26	0.78	0.89	1.32	1.07
PC 33:2; [M-Ac-H]-@5.94	ME217534	0.56	1.35	0.94	0.65	1.28	1.25
plasmenyl-PE 42:5; [M-H]-@7.90	ME217699	0.61	1.31	0.85	0.67	1.37	1.21
PC 35:2; [M-Ac-H]-@6.55	ME217545	0.64	1.22	0.77	0.75	1.36	1.26
PC 38:2; [M-Ac-H]-@7.38	ME217560	0.62	1.19	0.89	0.82	1.38	1.12
PI 35:1; [M-H]-@6.07	ME217643	0.72	1.14	0.89	0.76	1.36	1.13
PS 34:0; [M-H]-@7.41	ME217655	0.75	1.37	0.73	0.84	1.50	0.78
PC 38:4; [M-Ac-H]-@6.75	ME217563	0.63	1.57	0.53	0.79	1.52	0.89
lysoPE 18:0; [M-H]-@2.45	ME217661	0.68	1.53	0.59	0.83	1.40	0.94
lysoPE 22:5; [M-H]-@1.61	ME217671	0.71	1.54	0.71	0.80	1.31	0.90
PC 38:6; [M-Ac-H]-@5.98	ME217566	0.64	1.25	0.73	0.76	1.67	0.93
PE 37:5; [M-H]-@6.18	ME217613	0.69	1.11	0.80	0.66	1.76	0.97
PI 38:5; [M-H]-@5.46	ME217652	0.65	1.56	0.86	0.62	1.59	0.73
lysoPE 20:4; [M-H]-@1.36	ME217669	0.62	1.37	0.82	0.74	1.55	0.90
PC 38:7; [M-Ac-H]-@5.48	ME217567	0.59	1.34	1.01	0.64	1.58	0.89
PE 36:3; [M-H]-@5.19	ME217604	0.60	1.39	0.95	0.70	1.58	0.82
FFA(20:2)	ME217507	0.53	1.28	1.13	0.56	1.09	1.48
PC 42:2; [M-Ac-H]-@8.52	ME217579	0.62	1.27	0.99	0.76	1.06	1.34
PC 42:4; [M-Ac-H]-@7.75	ME217580	0.56	1.25	0.96	0.65	1.20	1.42
PE 36:2; [M-H]-@6.30	ME217601	0.52	1.07	1.10	0.63	1.33	1.41
PC 40:2; [M-Ac-H]-@8.00	ME217570	0.51	1.25	1.24	0.69	1.17	1.25
PE 38:1; [M-H]-@7.90	ME217614	0.67	1.08	1.21	0.68	1.15	1.29
plasmenyl-PE 32:0; [M-H]-@7.12	ME217674	0.69	1.21	1.13	0.68	1.17	1.18
Arachidonic acid	ME217490	0.72	1.24	1.17	0.87	0.94	1.13
FFA(18:2)	ME217504	0.77	1.19	1.21	0.90	0.86	1.14
FFA(20:1)	ME217506	0.72	1.16	1.22	0.86	0.91	1.21
FFA(22:0)	ME217508	0.67	1.36	0.93	0.83	1.06	1.17
MGDG 22:1; [M-H]-@1.47	ME217516	0.73	1.20	0.94	0.84	1.17	1.13
PC 38:1; [M-Ac-H]-@7.80	ME217559	0.68	1.25	1.05	0.82	1.09	1.16
PE 35:3; [M-H]-@6.27	ME217597	0.66	0.79	0.81	0.94	1.40	1.40
plasmenyl-PE 36:1; [M-H]-@7.75	ME217681	0.71	0.97	0.90	0.84	1.06	1.52
plasmenyl-PE 38:2; [M-H]-@7.90	ME217687	0.57	1.10	1.01	0.59	1.11	1.67
PC 40:0; [M-Ac-H]-@8.71	ME217569	0.42	1.20	0.83	0.58	1.40	1.60
plasmenyl-PE 38:1; [M-H]-@8.25	ME217686	0.42	1.24	0.93	0.50	1.37	1.58
plasmenyl-PE 40:3; [M-H]-@7.97	ME217693	0.55	1.14	0.86	0.65	1.41	1.40
PC 35:1; [M-Ac-H]-@7.02	ME217544	0.56	1.14	0.72	0.66	1.45	1.46
PC 36:1; [M-Ac-H]-@7.26	ME217548	0.53	1.05	0.79	0.71	1.51	1.41
PG 34:1; [M-H]-@5.95	ME217634	0.62	1.06	0.80	0.92	1.24	1.35
PE 34:1; [M-H]-@5.48	ME217591	0.65	0.99	0.75	0.79	1.35	1.46
PE 38:2; [M-H]-@6.91	ME217615	0.64	1.08	0.78	0.76	1.35	1.38
plasmenyl-PE 36:1; [M-H]-@7.13	ME217680	0.51	1.06	0.73	0.69	1.31	1.70
plasmenyl-PE 36:2; [M-H]-@7.34	ME217682	0.52	1.19	0.76	0.62	1.23	1.68
PC 42:1; [M-Ac-H]-@8.85	ME217578	0.74	1.03	0.72	0.66	1.25	1.57
PG 34:2; [M-H]-@5.54	ME217635	0.60	1.02	0.65	0.84	1.21	1.64
FFA(24:1)	ME217513	0.44	2.05	0.90	0.52	1.15	0.97
FFA(24:2)	ME217514	0.45	2.20	0.87	0.46	1.05	0.99
PC 29:0; [M-Ac-H]-@5.61	ME217523	0.31	1.58	0.92	0.41	1.71	1.13
lysoPE 22:4; [M-H]-@1.91	ME217670	0.42	1.69	0.76	0.38	1.71	1.05
PE 36:4; [M-H]-@4.69	ME217606	0.40	1.74	0.95	0.41	1.60	0.94
plasmenyl-PE 38:5; [M-H]-@6.78	ME217691	0.31	1.81	0.88	0.34	1.69	1.01
plasmenyl-PE 36:5; [M-H]-@6.35	ME217685	0.21	1.92	0.80	0.21	1.80	1.11
plasmenyl-PE 40:6; [M-H]-@7.19	ME217697	0.28	1.85	0.86	0.25	1.57	1.22
plasmenyl-PE 38:4; [M-H]-@7.05	ME217689	0.32	1.89	0.64	0.31	1.60	1.24
plasmenyl-PE 38:4; [M-H]-@7.29	ME217690	0.32	1.89	0.64	0.31	1.60	1.24
PC 32:0; [M-Ac-H]-@6.58	ME217528	0.31	2.12	0.84	0.30	1.51	0.96
PI 36:2; [M-H]-@5.99	ME217646	0.38	2.07	0.57	0.29	1.71	0.94
PI 40:5; [M-H]-@6.06	ME217653	0.40	1.92	0.57	0.41	1.78	0.90
lysoPE 19:0; [M-H]-@2.97	ME217665	0.63	1.89	0.61	0.72	1.25	0.85
plasmenyl-PE 34:3; [M-H]-@6.35	ME217679	0.48	1.87	0.65	0.69	1.30	0.99
PI 35:2; [M-H]-@5.63	ME217644	0.82	1.71	0.68	0.51	1.37	0.87
PI 36:1; [M-H]-@6.39	ME217645	0.63	1.82	0.65	0.55	1.37	0.95
PI 36:3; [M-H]-@5.46	ME217647	0.67	1.72	0.81	0.52	1.35	0.93
PI 34:1; [M-H]-@5.78	ME217641	0.56	1.64	0.69	0.64	1.43	1.02
lysoPE 20:1; [M-H]-@2.69	ME217666	0.50	1.57	0.81	0.63	1.50	1.00
PC 35:4; [M-Ac-H]-@5.89	ME217547	0.51	1.48	0.72	0.66	1.58	1.04
plasmenyl-PE 34:1; [M-H]-@7.18	ME217677	0.45	1.76	0.91	0.54	1.42	0.96
PE 38:5; [M-H]-@5.12	ME217620	0.47	1.75	0.67	0.63	1.60	0.87
plasmenyl-PE 32:1; [M-H]-@6.62	ME217675	0.46	1.89	0.76	0.48	1.57	0.85
lysoPE 24:0; [M-H]-@5.26	ME217673	0.30	1.96	0.84	0.30	1.23	1.41
FFA(22:1)	ME217509	0.38	1.69	0.92	0.48	1.28	1.30
FFA(22:2)	ME217510	0.34	1.70	0.93	0.45	1.25	1.38
PE 36:1; [M-H]-@6.11	ME217600	0.45	1.67	0.60	0.57	1.38	1.31
PG 36:3; [M-H]-@5.38	ME217637	0.45	1.62	0.59	0.59	1.44	1.29
PG 36:4; [M-H]-@4.94	ME217638	0.53	1.82	0.70	0.48	1.19	1.27
PC 33:0; [M-Ac-H]-@6.84	ME217532	0.52	1.74	0.78	0.55	1.30	1.12
plasmenyl-PE 36:3; [M-H]-@6.80	ME217683	0.47	1.70	0.78	0.51	1.33	1.22
CL 70:5; [M-2H](2-)@5.92	ME217493	0.38	0.81	0.98	0.49	2.00	1.40
PE 33:1; [M-H]-@6.57	ME217587	0.52	0.85	0.92	0.48	2.06	1.20
CL 74:5; [M-2H](2-)@6.75	ME217497	0.47	1.01	0.77	0.57	1.80	1.39
PE 34:3; [M-H]-@6.01	ME217593	0.41	0.97	0.89	0.45	1.88	1.43
plasmenyl-PE 42:4; [M-H]-@8.19	ME217698	0.43	1.05	0.89	0.48	1.75	1.44
lysoPE 16:1; [M-H]-@1.27	ME217659	0.44	0.94	0.87	0.33	2.04	1.42
PC 40:3; [M-Ac-H]-@7.60	ME217571	0.48	1.09	0.90	0.34	1.94	1.28
PC 34:4; [M-Ac-H]-@5.39	ME217542	0.26	0.94	1.07	0.23	1.89	1.70
PC 31:1; [M-Ac-H]-@5.75	ME217527	0.30	1.15	1.02	0.35	1.85	1.41
PC 34:2; [M-Ac-H]-@8.60	ME217539	0.28	1.18	0.98	0.47	1.66	1.49
PC 34:3; [M-Ac-H]-@5.76	ME217541	0.30	1.06	0.92	0.39	1.80	1.58
PC 36:5; [M-Ac-H]-@5.57	ME217552	0.35	1.01	1.01	0.40	1.69	1.61
lysoPE 20:3; [M-H]-@1.65	ME217668	0.52	1.25	0.81	0.68	1.56	1.20
plasmenyl-PE 42:6; [M-H]-@7.77	ME217700	0.43	1.15	0.89	0.63	1.64	1.29
PC 38:5; [M-Ac-H]-@6.26	ME217564	0.50	1.39	0.60	0.59	1.80	1.10
PC 38:5; [M-Ac-H]-@6.55	ME217565	0.53	1.42	0.63	0.62	1.63	1.14
PC 34:1; [M-Ac-H]-@6.66	ME217537	0.41	1.20	0.70	0.53	1.78	1.38
PC 42:9; [M-Ac-H]-@6.14	ME217582	0.54	1.25	0.67	0.59	1.71	1.21
PG 40:3; [M-H]-@6.11	ME217640	0.47	1.28	0.63	0.62	1.69	1.29
PC 36:4; [M-Ac-H]-@6.05	ME217551	0.40	1.27	0.86	0.52	1.59	1.40
plasmenyl-PE 40:5; [M-H]-@7.43	ME217696	0.35	1.36	0.82	0.43	1.60	1.46
PC 34:2; [M-Ac-H]-@7.52	ME217538	0.33	1.34	0.81	0.32	1.76	1.47
PC 34:2; [M-Ac-H]-@6.22	ME217540	0.34	1.45	0.77	0.42	1.70	1.35
PC 36:3; [M-Ac-H]-@6.38	ME217550	0.37	1.38	0.76	0.43	1.70	1.37
PC 36:2; [M-Ac-H]-@6.83	ME217549	0.46	1.55	0.67	0.58	1.53	1.21
PE 34:2; [M-H]-@6.39	ME217592	0.41	1.44	0.76	0.54	1.66	1.20
PC 30:0; [M-Ac-H]-@5.95	ME217524	0.36	1.55	0.75	0.47	1.57	1.32
plasmenyl-PE 38:3; [M-H]-@7.51	ME217688	0.41	1.49	0.68	0.50	1.60	1.32
lysoPE 18:1; [M-H]-@1.84	ME217662	0.50	1.49	0.84	0.55	1.45	1.17
lysoPE 18:2; [M-H]-@1.39	ME217663	0.45	1.48	0.95	0.49	1.53	1.14
plasmenyl-PE 40:4; [M-H]-@7.67	ME217694	0.49	1.37	0.81	0.55	1.44	1.36
plasmenyl-PE 40:4; [M-H]-@7.88	ME217695	0.49	1.37	0.81	0.55	1.44	1.36
PC 33:1; [M-Ac-H]-@6.41	ME217533	0.42	1.42	0.75	0.56	1.49	1.37
PC 35:3; [M-Ac-H]-@6.10	ME217546	0.42	1.46	0.77	0.56	1.52	1.28
CerP 34:1; [M-H]-@5.83	ME217500	0.41	1.43	0.91	0.49	1.41	1.40
PC 33:3; [M-Ac-H]-@5.55	ME217535	0.44	1.36	1.00	0.55	1.34	1.36
PC 28:0; [M-Ac-H]-@5.24	ME217522	0.25	1.43	0.94	0.20	1.94	1.30
PC 32:2; [M-Ac-H]-@5.61	ME217530	0.22	1.42	0.96	0.21	1.85	1.40
PC 30:1; [M-Ac-H]-@5.43	ME217525	0.24	1.54	0.88	0.27	1.83	1.30
PC 31:0; [M-Ac-H]-@6.22	ME217526	0.31	1.48	0.75	0.29	1.88	1.32
PC 44:4; [M-Ac-H]-@8.45	ME217583	0.38	1.36	1.07	0.30	1.71	1.26
FFA(22:3)	ME217511	0.42	1.21	1.11	0.41	1.79	1.14
lysoPE 18:3; [M-H]-@1.13	ME217664	0.42	1.37	0.94	0.45	1.75	1.13
PI 38:4; [M-H]-@5.99	ME217651	0.54	1.83	0.44	0.59	1.83	0.71
PE 38:6; [M-H]-@4.74	ME217622	0.44	1.56	0.80	0.73	1.84	0.64
PC 37:5; [M-Ac-H]-@6.09	ME217558	0.46	1.64	0.58	0.46	1.91	0.93
lysoPE 22:6; [M-H]-@1.33	ME217672	0.59	1.54	0.62	0.62	1.71	0.87
PC 37:4; [M-Ac-H]-@6.59	ME217557	0.61	1.40	0.58	0.58	1.97	0.81
PI 36:4; [M-H]-@4.97	ME217648	0.25	1.49	0.81	0.27	2.26	0.95
PC 32:1; [M-Ac-H]-@6.08	ME217529	0.17	1.67	0.73	0.12	2.20	1.14
PI 34:2; [M-H]-@5.34	ME217642	0.30	1.64	0.80	0.25	1.93	1.10
plasmenyl-PE 36:4; [M-H]-@6.70	ME217684	0.24	1.66	0.74	0.25	1.97	1.16
lysoPE 20:2; [M-H]-@2.09	ME217667	0.36	1.14	0.68	0.25	2.44	1.13
PE 32:1; [M-H]-@6.27	ME217586	0.36	0.99	0.83	0.40	2.34	1.10
CL 74:3; [M-2H](2-)@7.07	ME217496	0.53	1.05	0.81	0.63	1.94	1.05
PC 40:6; [M-Ac-H]-@6.56	ME217574	0.55	1.20	0.68	0.52	2.13	0.91
PC 37:3; [M-Ac-H]-@6.71	ME217556	0.43	1.26	0.92	0.45	2.00	0.99
PC 40:7; [M-Ac-H]-@6.11	ME217575	0.45	1.31	0.73	0.50	1.98	1.04

Factors:

F1	lipitor:NO \| visit:1 week
F2	lipitor:NO \| visit:20 weeks
F3	lipitor:NO \| visit:8 weeks
F4	lipitor:YES \| visit:1 week
F5	lipitor:YES \| visit:20 weeks
F6	lipitor:YES \| visit:8 weeks

Data matrix